Fig 1: Targeting ACSL5 and FAO reverses SS symptoms in vivo. (A) Correlations of ACSL5 expression with disease stage (GSE23117). (B) Schematic of the adoptive transfer of CD4+ T cells, followed by ESS induction and in vivo evaluation of disease severity and T-cell phenotypes. (C) H&E staining of representative salivary glands and quantification of histological scores and lymphocyte foci (scale bar = 50-500 μm). The black boxes indicate lymphocytic foci. (D) Serum SSA and SSB levels in the indicated groups. (E) CD4+ T-cell and T-cell subpopulation ratios in the spleens of the indicated groups. (F) CD4+ T-cell and T-cell subpopulation ratios in the lymph nodes of the indicated groups. (G) CD4+ T-cell and T-cell subpopulation ratios in the submandibular salivary glands of the indicated groups. (H) Representative plots of CD4+ T cells in the spleen and lymph nodes of the indicated groups. (I) Representative plots of T-cell subpopulations in the spleen, lymph nodes, and submandibular salivary glands of the indicated groups. (J) H&E staining of representative salivary glands and quantification of disease severity (scale bar = 100-1000 μm). (K) Flow cytometry of T-cell subpopulations in Triacsin C/etomoxir-treated vs. control mice at 12 weeks of age. The data are presented as the means ± SDs. n = 15 biological replicates for panel A, and n = 5 biological replicates for panels C-K. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Statistical analyses were performed using two-tailed tests, two-way ANOVA, and one-way ANOVA.